In conclusion, to date, there is as yet no consensus among the different studies in which response to tamoxifen has been correlated with expression of ERβ and/or the ERβ2/βcx variant as to whether measuring ERβ expression in ERα-positive breast cancers is likely to be informative as regards response to anti-oestrogen therapy. The gene discussed is ESR2; the disease is breast carcinoma.